POM-V Prescription Required Companion Animal

Rheumocam 0.5mg/ml Oral Suspension for Cats

Active ingredient: Meloxicam

Form

Liquid

Species

Cats

Manufacturer

Chanelle Pharmaceuticals Manufacturing Ltd

VMD MA No.

08749/5017

What it's used for

Alleviation of mild to moderate post-operative pain and inflammation following surgical procedures in cats, e.g. orthopaedic and soft tissue surgery. Allev...

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Meloxicam

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Rheumocam 0.5mg/ml Oral Suspension for Cats — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 26 Mar 2026.

Alleviation of mild to moderate post-operative pain and inflammation following surgical
procedures in cats, e.g. orthopaedic and soft tissue surgery.
Alleviation of pain and inflammation in acute and chronic musculo-skeletal disorders in
cats.

Oral use.
Post-operative pain and inflammation following surgical procedures:
After initial treatment with Rheumocam 5 mg/ml solution for injection for cats, continue
treatment 24 hours later with Rheumocam 0.5 mg/ml oral suspension for cats at a
dosage of 0.05 mg meloxicam/kg body weight. The oral follow-up dose may be
administered once daily (at 24-hour intervals) for up to four days.
Acute musculo-skeletal disorders:
Initial treatment is a single oral dose of 0.2 mg meloxicam/kg body weight on the first
day. Treatment is to be continued once daily by oral administration (at 24-hour intervals)
at a dose of 0.05 mg meloxicam/kg body weight for as long as acute pain and
inflammation persist.
Chronic musculo-skeletal disorders:
Initial treatment is a single oral dose of 0.1 mg meloxicam/kg body weight on the first
day. Treatment is to be continued once daily by oral administration (at 24-hour intervals)
at a maintenance dose of 0.05 mg meloxicam/kg body weight. A clinical response is
normally seen within 7 days. Treatment should be discontinued after 14 days at the
latest if no clinical improvement is apparent.
Route and method of administration:
The syringe fits onto the drop dispenser of the bottle and has a kg-body weight scale
which corresponds to the dose of 0.05 mg meloxicam/kg bodyweight. Thus for initiation
of the treatment of chronic musculo-skeletal disorders on the first day, twice the
maintenance volume will be required.

Issued: April 2022
AN: 02150/2021
For initiation of the treatment of acute musculo-skeletal disorders on the first day, 4
times the maintenance volume will be required.
Shake well before use. To be administered orally either mixed with food or directly into
the mouth. Particular care should be taken with regard to the accuracy of dosing. The
recommended dose should not be exceeded.
Avoid introduction of contamination during use.

Do not use in pregnant or lactating animals.
Do not use in cats suffering from gastrointestinal disorders such as irritation and
haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.
Do not use in case of hypersensitivity to the active substance or to any of the excipients.
Do not use in cats less than 6 weeks of age.

Issued: April 2022
AN: 02150/2021

Typical adverse reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea,
faecal occult blood, lethargy and renal failure have occasionally been reported.
Gastrointestinal ulceration and elevated liver enzymes were reported in very rare cases.
These side effects are in most cases transient and disappear following termination of
the treatment but in very rare cases may be serious or fatal.
If adverse reactions occur, treatment should be discontinued and the advice of a
veterinarian should be sought.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reactions)
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

Issued: April 2022
AN: 02150/2021

None.

Special precautions for use in animals
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a
potential risk of renal toxicity.
Post-operative pain and inflammation following surgical procedures:
In case additional pain relief is required, multimodal pain therapy should be considered.
Chronic musculoskeletal disorders:
Response to long-term therapy should be monitored at regular intervals by a veterinary
surgeon.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
People with known hypersensitivity to non-steroidal anti-Inflammatory drugs (NSAIDs)
should avoid contact with the veterinary medicinal product.
In case of accidental ingestion, seek medical advice immediately and show the package
leaflet or the label to the physician.

Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances
with high protein binding may compete for binding and thus lead to toxic effects.
Rheumocam must not be administered in conjunction with other NSAIDs or
glucocorticosteroids. Concurrent administration of potential nephrotoxic veterinary
medicinal products should be avoided.
Pre-treatment with anti-inflammatory substances may result in additional or increased
adverse effects and accordingly a treatment-free period with such veterinary medicinal
products should be observed for at least 24 hours before commencement of treatment.
The treatment-free period, however, should take into account the pharmacological
properties of the products used previously.

This veterinary medicinal product does not require any special storage conditions.

Not applicable.
5.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.